Publications by authors named "Pablo Bedano"
Article Synopsis
- The study evaluates the effectiveness of targeted agents, specifically pertuzumab plus trastuzumab, in patients with advanced biliary tract cancer (BTC) who have specific genomic alterations.
- Out of 29 enrolled patients, the treatment showed a 40% disease control rate, with some experiencing significant responses, indicating potential benefits of this combination therapy.
- Although the treatment was generally well-received, a few patients reported notable adverse events, highlighting the importance of monitoring safety alongside treatment efficacy.
Introduction: Bevacizumab when combined with carboplatin and paclitaxel improves response rates (RRs) and overall survival in patients with advanced non-small cell lung cancer. Paclitaxel has single-agent activity in relapsed small cell lung cancer (SCLC). Angiogenesis seems to play an important role in the pathogenesis of SCLC.
View Article and Find Full Text PDFPatients with advanced non-small cell lung cancer continue to have a poor prognosis; most die from the disease within 1 year. Chemotherapy is beneficial for some patients in the first-line metastatic setting. Three agents, namely docetaxel, pemetrexed, and erlotinib, are approved by the United States Food and Drug Administration as treatment in the second-line setting.
View Article and Find Full Text PDFPurpose: Initial cisplatin (CIS) combination chemotherapy will cure 70% of patients with disseminated testicular cancer. This phase II clinical trial evaluated the combination of CIS plus epirubicin (CIS-EPI) in patients with metastatic germ cell tumors (GCT) not amenable to cure with standard salvage therapy.
Patients And Methods: Between March 2001 and August 2005, 30 patients with GCT, who had received at least one previous CIS-based regimen, were enrolled.